[co-authors: Sean Feely, Senior Public Policy Specialist and Julie E. Nolan, Senior Policy Advisor]

• On September 19, Speaker Pelosi released a drug pricing plan that includes proposals for Medicare direct price negotiation and international reference pricing.

• The Speaker's plan overlaps with policies contained in the Senate Finance Committee's drug pricing package and the administration's proposed International Pricing Index (IPI) Model, all of which highlight key divides among lawmakers.

• There is a narrow path forward for a year-end deal on drug pricing, and some expect negotiations on the issue could carry into 2020.

House Speaker Nancy Pelosi (D-CA) released her long-awaited prescription drug pricing plan on September 19, the Lower Drug Costs Now Act (H.R. 3). The legislation combines Medicare drug price negotiation, international reference pricing, inflationary rebates and several Medicare Part D reforms in a bid to lower prices in the public and commercial insurance markets.